Hal Landy is a physician with 40 years of clinical research experience developing novel therapeutics primarily for rare genetic diseases. Therapeutics have included protein replacement therapies, exon-skipping compounds and gene therapies.

Since 2007, Dr. Landy has served as Chief Medical Officer or chief medical consultant for numerous start-up biotech companies and mid-size pharmaceutical companies. Notable approvals include Myozyme for Pompe disease, Strensiq for hypophosphatasia and Brineura for late-infantile Batten disease. He has also served as Principal Investigator on FDA and Department of Defense grants.

He was educated at Harvard College and Columbia University, trained at Massachusetts General Hospital and at Children’s Hospital, Boston and was on staff at Children’s Hospital and Harvard Medical School until 1996. He has authored or co-authored over 20 peer-reviewed articles and book chapters.